The reverse vesicle composition of the present invention includes (A) a sphingosine represented by formula (1) (wherein R 1 represents a C4 to C30 linear alkyl group which may be substituted by a hydroxyl group, a carbonyl group and or an amino group Y represents a methylene group, a methine group and or an oxygen atom each of X 1, X 2, and X 3 represents a hydrogen atom, a hydroxyl group and or an acetoxy group X 4 represents a hydrogen atom, an acetyl group, or a glyceryl group and or forms an oxo group together with the adjacent oxygen atom (wherein when Y is a methine group, one of X 1 and X 2 is a hydrogen atom, and the other is absent and when X 4 forms an oxo group, X 3 is absent) each of R 2 and R 3 represents a hydrogen atom, a hydroxyl group, a hydroxyethyl group and or an acetoxymethyl group a is a number of 2 or 3 each of (R) a represents a hydrogen atom, an amidino group, or a linear-chain alkyl group optionally having a substituent selected from among a hydroxyl group, a hydroxyalkoxy group, an alkoxy group and an acetoxy group and containing 1 to 8 carbon atoms in total and the broken line represents an optional unsaturated bond), (B) a C16 to C30 fatty acid, (C) a hydrocarbon oil, (D) an ester oil which is in liquid form at 25C and (F) water and wherein the ratio by mass of ingredient (C) to ingredient (D) satisfies the following relationship: 1 (C)/(D)< 1000, and the composition contains a surfactant having a molecular weight of 1,000 or less in an amount of 1 mass% or less.
